Azide complexes [M(RN(3))(CO)(3)P(2)]BPh(4)[M = Mn, Re; R = C(6)H(5)CH(2), 4-CH(3)C(6)H(4)CH(2), C(6)H(5), 4-CH(3)C(6)H(4), C(5)H(9); P = PPh(OEt)(2), PPh(2)(OEt)] were prepared by allowing tricarbonyl MH(CO)(3)P(2) hydride complexes to react first with Brønsted acid (HBF(4), CF(3)SO(3)H) and then with organic azide in the dark. In sunlight the reaction yielded tetraazabutadiene [M(eta(2)-1,4-R(2)N(4))(CO)(2)P(2)]BPh(4) complexes or, with benzyl azide, imine [M{eta(1)-NH[double bond, length as m-dash]C(H)Ar}(CO)(3)P(2)]BPh(4)(Ar = C(6)H(5), 4-CH(3)C(6)H(4)) derivatives. Tetraazabutadiene [M(eta(2)-1,4-R(2)N(4))(CO)(2)P(2)]BPh(4) complexes were also prepared by reacting dicarbonyl MH(CO)(2)P(3) species first with Brønsted acid and then with an excess of organic azide. Complexes were characterised spectroscopically (IR, (1)H, (31)P, (13)C, (15)N NMR data) and by the X-ray crystal structure determination of complex [Re{eta(2)-1,4-(C(6)H(5)CH(2))(2)N(4)}(CO)(2){PPh(OEt)(2)}(2)]BPh(4)(). Strong evidence for coordination of the organic azide was obtained from the (15)N NMR spectra of labelled [M(C(6)H(5)CH(2)(15)NN(15)N)(CO)(3)P(2)]BPh(4) derivatives.
No takes yet. Share an insight, caveat, or question.
Albertin et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: